title: Protective effect of hydrogen sulfide on hyperbaric hyperoxia-induced lung injury in a rat model.
abstract: Hyperbaric oxygen therapy is one of the most widely used clinical interventions to counteract insufficient pulmonary oxygen delivery in patients with severe lung injury. However, prolonged exposure to hyperoxia leads to inflammation and acute lung injury. This study aimed to investigate the protective effect of hydrogen sulfide on hyperbaric hyperoxia-induced lung injury. Rats were intraperitoneally treated with sodium hydrosulphide (NaHS) at 28 μmol/kg immediately before hyperoxia exposure and then exposed to pure oxygen at 2.5 atmospheres absolute (atm abs) with continuous ventilation for six hours, Immediately after hyperoxia exposure, rats were sacrificed via anesthesia. The bronchoalveolar lavage fluid (BALF) was harvested for the detection of protein concentration and IL-1 content, and the lungs were collected for HE staining, TUNEL staining and detection of wet/dry weight ratio. Our results showed hyperbaric hyperoixa exposure could significantly damage the lung (HE staining), increase the protein and IL-13 in the BALF, elevate the wet/dry Weight ratio and raise the TUNEL positive cells. However, pre-treatment with hydrogen sulfide improved the lung morphology, reduced the TUNEL positive cells and attenuated the lung inflammation (reduction in IL-13 of BALF and HE staining). Taken together, our findings indicate that hydrogen sulfide pretreatment may exert protective effects on hyperbaric hyperoxia-induced lung injury.
authors.affiliation: Department of Diving Medicine, Second Military Medical University, Shanghai, P.R. China.
authors.forename: Wenwu
authors.initials: W
authors.lastname: Liu
authors.forename: Kehuan
authors.initials: K
authors.lastname: Liu
authors.forename: Chunqing
authors.initials: C
authors.lastname: Ma
authors.forename: Jiangang
authors.initials: J
authors.lastname: Yu
authors.forename: Zhaoyun
authors.initials: Z
authors.lastname: Peng
authors.forename: Guoyang
authors.initials: G
authors.lastname: Huang
authors.forename: Zhiyu
authors.initials: Z
authors.lastname: Cai
authors.forename: Runping
authors.initials: R
authors.lastname: Li
authors.forename: Weigang
authors.initials: W
authors.lastname: Xu
authors.forename: Xuejun
authors.initials: X
authors.lastname: Sun
authors.forename: Kan
authors.initials: K
authors.lastname: Liu
authors.forename: Juan
authors.initials: J
authors.lastname: Zheng
mesh_terms: D055371:Acute Lung Injury / Q000209:etiology / Q000517:prevention & control*; D000818:Animals; D000873:Anthracenes; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D064426:Gasotransmitters / Q000627:therapeutic use*; D006862:Hydrogen Sulfide / Q000627:therapeutic use*; D006931:Hyperbaric Oxygenation / Q000009:adverse effects*; D020287:In Situ Nick-End Labeling; D007274:Injections, Intraperitoneal; D053583:Interleukin-1beta / Q000032:analysis; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D011506:Proteins / Q000032:analysis; D017207:Rats, Sprague-Dawley; D013440:Sulfides / Q000494:pharmacology
chemical_list: C546739:AnOV compound; D000873:Anthracenes; D064426:Gasotransmitters; D053583:Interleukin-1beta; D011506:Proteins; D013440:Sulfides; C025451:sodium bisulfide; D006862:Hydrogen Sulfide